Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)

Gilead Sciences (GILD) has reported Current Deferred Revenue for 8 consecutive years, with $202.0 million the latest figure, recorded in Q4 2016.

• Current Deferred Revenue for Q4 2016 came in at $202.0 million, down 54.09% year-over-year; the trailing twelve-month figure through Dec 2016 was $202.0 million (down 54.09% YoY), and the FY2016 annual result was $202.0 million, down 54.09% from the prior year.
• Current Deferred Revenue was $202.0 million for Q4 2016 at Gilead Sciences, down from $361.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $529.0 million in Q1 2016 and troughed at $93.7 million in Q2 2012.
• Average Current Deferred Revenue over 5 years is $214.2 million, with a median of $126.8 million recorded in 2013.
• Year-over-year, Current Deferred Revenue jumped 296.72% in 2015 and slumped 54.09% in 2016.
• Over 5 years, Current Deferred Revenue stood at $103.2 million in 2012, then gained by 7.6% to $111.0 million in 2013, then advanced by 20.72% to $134.0 million in 2014, then surged by 228.36% to $440.0 million in 2015, then plunged by 54.09% to $202.0 million in 2016.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $202.0 million in Q4 2016, $361.0 million in Q3 2016, and $345.0 million in Q2 2016.